GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 12:35:04 2024-03-28 pm EDT 5-day change 1st Jan Change
1,709 GBX +0.20% Intraday chart for GSK plc +2.08% +17.82%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
GSK : Sell rating from JP Morgan ZD
U.S. FDA approves Akebia's anemia drug RE
GSK FILES FOR DEBT SHELF; SIZE NOT DISCLOSED - SEC FILING… RE
Moderna, Inc. prepares for the post-Covid era Our Logo
British Drugmaker GSK to Introduce Price Cap on Inhaled Products from 2025 MT
GSK to cap out-of-pocket inhaler costs in US RE
GSK Announces Cap Of $35 Per Month On U.S. Patient Out-Of-Pocket Costs RE
GSK - PROGRAM IS WIDE REACHING AND WILL BE IMPLEMENTED NO LATER… RE
GSK ANNOUNCES CAP OF $35 PER MONTH ON U.S. PATIENT OUT-OF-POCKET… RE
GSK : Buy rating from Jefferies ZD
CAC40: Paris and E-Stoxx50 close at record highs CF
Repeat & Correct : Pfizer to Raise Around $3.5 Billion From Haleon Shares Sale -- Update DJ
CAC40: in record territory, oil at year's high CF
GSK : UBS reaffirms its Buy rating ZD
UBS Keeps GSK at Buy, Lifts PT MT
Moody's Confirms GSK's Ratings on Strong Performance, Solid Growth Prospects MT
Pfizer to Raise Around $4.27 Billion From Haleon Shares Sale -- Update DJ
CAC40: new rebound after BoJ and ZEW indexes CF
GSK : UBS raises its target price CF
Investec cuts ConvaTec; RBC raises Vistry AN
Pfizer offloads $3.9 bln stake in Sensodyne-maker Haleon RE
CAC 40: no major upheaval after BoJ meeting CF
Health Care Up as Traders Await Policy Statement -- Health Care Roundup DJ
GSK's Jemperli Combination Shows Potential in Endometrial Cancer Trial MT
Pfizer: Haleon shareholding to be reduced to 24%. CF
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
17.05 GBP
Average target price
19.89 GBP
Spread / Average Target
+16.64%
Consensus
  1. Stock
  2. Equities
  3. Stock GSK plc - London S.E.
  4. News GSK plc
  5. GlaxoSmithKline : GSK, Vir Signs Procurement Agreement For COVID-19 Treatment With EU